Cardia Bioplastics (ASX:CNN) Change In Working Capital : A$0.00 Mil (TTM As of Dec. 2023)

View and export this data going back to . Start your Free Trial

What is Cardia Bioplastics Change In Working Capital?

Cardia Bioplastics's change in working capital for the quarter that ended in Dec. 2023 was A$0.00 Mil.

Cardia Bioplastics's change in working capital for the fiscal year that ended in Jun. 2023 was A$0.00 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

Cardia Bioplastics Change In Working Capital Historical Data

The historical data trend for Cardia Bioplastics's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cardia Bioplastics Change In Working Capital Chart

Cardia Bioplastics Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Change In Working Capital

Get a 7-Day Free Trial

Cardia Bioplastics Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Change In Working Capital	Get a 7-Day Free Trial															-	-	-	-	-

Cardia Bioplastics Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.00 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

Cardia Bioplastics Change In Working Capital Related Terms

Thank you for viewing the detailed overview of Cardia Bioplastics's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Cardia Bioplastics (ASX:CNN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Consumer Cyclical » Packaging & Containers » Cardia Bioplastics Ltd (ASX:CNN) » Definitions » Change In Working Capital

Comparable Companies

Traded in Other Exchanges

SES:Australia

Address

247 Ferntree Gully Road, Unit 1, Mount Waverley, Melbourne, VIC, AUS, VIC 3149

Website

https://www.secosgroup.com.au

SECOS Group Ltd is an Australian developer and manufacturer of sustainable packaging materials. . Business operating segment includes the manufacture and distribution of polyethylene films, renewable resource-based resins, and finished products. It supplies proprietary biodegradable resins, packaging products cast films to a customer base spread globally.SECOS Global Application Development Centre is in Australia. Product Development Centre and manufacturing plant for resins and finished products in China and resins plant in Malaysia. It also has manufacturing plants for cast films in Malaysia. It conducts sales via geographical regions that include Australia, Asia, America, Europe, and Africa. Asia generates maximum revenue for the company.

Cardia Bioplastics (ASX:CNN) Headlines

No Headlines